{"a":[{"_":"Beyond clinical endpoints: Rethinking ALS drug development through disease biology","$":{"href":"/sponsored/beyond-clinical-endpoints-rethinking-als-drug-development-through-disease-biology","hreflang":"en"}}]}

Summary

Article discusses a new era in ALS drug development that combines established efficacy measures like survival and ALSFRS-R with biology-driven science to better capture disease heterogeneity. No specific clinical data, approvals, or company announcements are detailed.